Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics
Top Cited Papers
- 26 March 2003
- journal article
- clinical trial
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 306 (1) , 73-83
- https://doi.org/10.1124/jpet.103.049882
Abstract
The effects of the South American psychotropic beverage ayahuasca on subjective and cardiovascular variables and urine monoamine metabolite excretion were evaluated, together with the drug's pharmacokinetic profile, in a double-blind placebo-controlled clinical trial. This pharmacologically complex tea, commonly obtained from Banisteriopsis caapi and Psychotria viridis, combines N,N-dimethyltryptamine (DMT), an orally labile psychedelic agent showing 5-hydroxytryptamine2A agonist activity, with monoamine oxidase (MAO)-inhibiting β-carboline alkaloids (harmine, harmaline, and tetrahydroharmine). Eighteen volunteers with prior experience in the use of psychedelics received single oral doses of encapsulated freeze-dried ayahuasca (0.6 and 0.85 mg of DMT/kg of body weight) and placebo. Ayahuasca produced significant subjective effects, peaking between 1.5 and 2 h, involving perceptual modifications and increases in ratings of positive mood and activation. Diastolic blood pressure showed a significant increase at the high dose (9 mm Hg at 75 min), whereas systolic blood pressure and heart rate were moderately and nonsignificantly increased. Cmax values for DMT after the low and high ayahuasca doses were 12.14 ng/ml and 17.44 ng/ml, respectively. Tmax (median) was observed at 1.5 h after both doses. The Tmax for DMT coincided with the peak of subjective effects. Drug administration increased urinary normetanephrine excretion, but, contrary to the typical MAO-inhibitor effect profile, deaminated monoamine metabolite levels were not decreased. This and the negligible harmine plasma levels found suggest a predominantly peripheral (gastrointestinal and liver) site of action for harmine. MAO inhibition at this level would suffice to prevent first-pass metabolism of DMT and allow its access to systemic circulation and the central nervous system.Keywords
This publication has 31 references indexed in Scilit:
- Contribution of Individual Cytochrome P450 Isozymes to the O-Demethylation of the Psychotropic β-Carboline Alkaloids Harmaline and HarmineThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Determination of N,N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of AyahuascaJournal of Chromatography B, 2002
- Psychometric assessment of the Hallucinogen Rating ScaleDrug and Alcohol Dependence, 2001
- Pharmacology of MDMA in HumansAnnals of the New York Academy of Sciences, 2000
- Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C ReceptorsPharmacology Biochemistry and Behavior, 1998
- Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI)Drug and Alcohol Dependence, 1994
- Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of AyahuascaJournal of Ethnopharmacology, 1984
- Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidaseBiochemical Pharmacology, 1981
- Monoamine oxidase inhibition in brain and liver produced by β-carbolines: structure-activity relationships and substrate specificityBiochemical Pharmacology, 1977
- D-lysergic acid diethylamide (LSD)—Effect on biogenic amines excretion in manBiochemical Pharmacology, 1973